Allena Pharmaceuticals, Inc. filed its 10-K on Mar 31, 2022 for the period ending Dec 31, 2021. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Allena Pharmaceuticals, Inc.
Equities
ALNA
US0181191075
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+12.22% | 116B | |
+12.33% | 106B | |
-8.75% | 23.89B | |
-1.95% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-14.37% | 16.33B | |
+7.82% | 14.14B | |
+31.56% | 12.02B |